Full-Exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Vaca Paniagua, Felipe ^a   Alvarez Gomez, Rosa María ^a   Fragoso Ontiveros, Verónica ^a   Vidal Millan, Silvia ^a   Herrera, Luis Alonso ^b   Cantú, David ^a   Bargallo Rocha, Enrique ^a   Mohar, Alejandro ^b   López Camarillo, César ^c   Pérez Plasencia, Carlos ^a,d  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Universidad Nacional Autónoma de México ^*  (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNIC GROUP; EXON; FEMALE; GENE LOCATION; GENE SEQUENCE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTRON; MALE; MEXICAN; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PYROSEQUENCING; STOP CODON; TUMOR SUPPRESSOR GENE; WOMEN'S HEALTH; BREAST; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MEXICO; MUTATION; OVARY; OVARY TUMOR; PEDIGREE;

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MEXICO; OVARIAN NEOPLASMS; OVARY; PEDIGREE; YOUNG ADULT;

EID: 84861399847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037432     Document Type: Article

References (53)

1. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler R, (2011) Hereditary Breast and Ovarian Cancer: New Genes, New Treatments, New Concepts. Deutsches Ärzteblatt International 108: 323.
2. Narod SA, Foulkes WD, (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4: 665-676 doi:10.1038/nrc1431.
3. Petrucelli N, Daly MB, Feldman GL, (2010) Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics in Medicine 12: 245-259 doi:10.1097/GIM.0b013e3181d38f2f.
4. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, et al. (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30: 230-236.
5. Lynch HT, Deters CA, Snyder CL, Lynch JF, Villeneuve P, et al. (2005) BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 158: 119-125 doi:10.1016/j.cancergencyto.2004.01.032.
6. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, et al. (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1-12.
7. Pruthi S, Gostout BS, Lindor NM, (2010) Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clinic Proceedings 85: 1111-1120.
8. Paradiso A, Formenti S, (2011) Hereditary breast cancer: clinical features and risk reduction strategies. Annals of Oncology 22: i31-i36 doi:10.1093/annonc/mdq663.
9. Clark AS, Domchek SM, (2011) Clinical management of hereditary breast cancer syndromes. J Mammary Gland Biol Neoplasia 16: 17-25 doi:10.1007/s10911-011-9200-x.
10. Gerhardus A, Schleberger H, Schlegelberger B, Gadzicki D, (2007) Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. Eur J Hum Genet 15: 619-627 doi:10.1038/sj.ejhg.5201806.
11. Wang G, Beattie MS, Ponce NA, Phillips KA, (2011) Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genetics in Medicine 13: 1045-1050 doi:10.1097/GIM.0b013e31822a8113.
12. De Leeneer K, Hellemans J, De Schrijver J, Baetens M, Poppe B, et al. (2011) Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. Hum Mutat 32 (3): 335-344.
13. Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez U, Robles-Vidal C, et al. (2009) Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. European journal of gynaecological oncology 30: 527.
14. Théry J, Krieger S, Gaildrat P, Révillion F, (2011) Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet. 19 (10): 1052-1058.
15. Szabo CI, King M-C, (1995) Inherited breast and ovarian cancer. Hum Mol Genet 4 Spec No pp. 1811-1817.
16. Easton DF, Ford D, Bishop DT, (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271.
17. Chen S, Parmigiani G, (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 25: 1329-1333 doi:10.1200/JCO.2006.09.1066.
18. Kwon JS, Daniels MS, Sun CC, Lu KH, (2010) Preventing future cancers by testing women with ovarian cancer for BRCA mutations. Journal of Clinical Oncology 28: 675-682 doi:10.1200/JCO.2008.21.4684.
19. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, et al. (2010) The role of BRCA mutation testing in determining breast cancer therapy. Nature Publishing Group 7: 708-717 doi:10.1038/nrclinonc.2010.175.
20. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al. (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244.
21. Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, et al. (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18 (Suppl 6): vi93-8 doi:10.1093/annonc/mdm234.
22. Zhang L, Kirchhoff T, Yee CJ, Offit K, (2009) A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing. J Mol Diagn 11: 176-181 doi:10.2353/jmoldx.2009.080137.
23. Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderon-Garcidueñas AL, Chopin S, et al. (2002) BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat 20: 474-475 doi:10.1002/humu.9084.
24. Gutiérrez Espeleta G, Llacuachaqui M, García-Jiménez L, Aguilar Herrera M, Loáiciga Vega K, et al. (2011) BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clinical Genetics doi:10.1111/j.1399-0004.2011.01774.x.
25. Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, et al. (2011) Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 13: R107 doi:10.1186/bcr3049.
26. Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, et al. (2007) BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 16: 280-292 doi:10.1016/j.breast.2006.12.003.
27. de Sanjosé S, Léoné M, Bérez V, Izquierdo A, Font R, et al. (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 106: 588-593 doi:10.1002/ijc.11271.
28. Møller P, Hagen AI, Apold J, Maehle L, Clark N, et al. (2007) Genetic epidemiology of BRCA mutations-family history detects less than 50% of the mutation carriers. Eur J Cancer 43: 1713-1717.
29. Thompson D, Easton D, Breast Cancer Linkage Consortium, (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68: 410-419 doi:10.1086/318181.
30. Lecarpentier J, Noguès C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, et al. (2011) Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Res Treat 130: 927-938 doi:10.1007/s10549-011-1655-3.
31. Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, et al. (2010) Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 119: 221-232 doi:10.1007/s10549-009-0394-1.
32. Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P, (2006) Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat 98: 285-294 doi:10.1007/s10549-006-9161-8.
33. Gilles A, Meglécz E, Pech N, Ferreira S, Malausa T, et al. (2011) Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 12: 245 doi:10.1186/1471-2164-12-245.
34. Hofmann W, Görgens H, John A, Horn D, Hüttner C, et al. (2003) Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. Hum Mutat 22: 103-104.
35. Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, et al. (2003) Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet 12: 1055-1061.
36. Ewald IP, Ribeiro PLI, Palmero EI, Cossio SL, Giugliani R, et al. (2009) Genomic rearrangements in BRCA1 and BRCA2: A literature review. Genet Mol Biol 32: 437-446 doi:10.1590/S1415-47572009005000049.
37. De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K, (2009) Genotyping of frequent BRCA1/2 SNPs with unlabeled probes: a supplement to HRMCA mutation scanning, allowing the strong reduction of sequencing burden. J Mol Diagn 11: 415-419 doi:10.2353/jmoldx.2009.090032.
38. Blanco A, la Hoya de M, Balmaña J, Ramón y Cajal T, Teulé A, et al. (2011) Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat doi:10.1007/s10549-011-1842-2.
39. Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, et al. (2011) Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations. Breast Cancer Res Treat 130: 207-215 doi:10.1007/s10549-011-1548-5.
40. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410-414 doi:10.1038/ng.569.
41. Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, et al. (2011) Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat 130: 1003-1010 doi:10.1007/s10549-011-1677-x.
42. Liu HX, Cartegni L, Zhang MQ, Krainer AR, (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27: 55-58 doi:10.1038/83762.
43. Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, et al. (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67: 1494-1501 doi:10.1158/0008-5472.CAN-06-3297.
44. Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, et al. (2008) Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. Eur J Hum Genet 16: 820-832 doi:10.1038/ejhg.2008.13.
45. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, et al. (2006) Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure. Science 314: 1930-1933 doi:10.1126/science.1131262.
46. Duan J, (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205-216 doi:10.1093/hmg/ddg055.
47. Liede A, Malik IA, Aziz Z, Rios Pd P de L, Kwan E, et al. (2002) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71: 595-606.
48. Evans DGR, Neuhausen SL, Bulman M, Young K, Gokhale D, et al. (2004) Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. Journal of Medical Genetics 41: e21.
49. Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, et al. (2006) Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 7: 75 doi:10.1186/1471-2350-7-75.
50. Salazar R, Cruz-Hernandez JJ, Sanchez-Valdivieso E, Rodriguez CA, Gomez-Bernal A, et al. (2006) BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain. Cancer Letters 233: 172-177 doi:10.1016/j.canlet.2005.03.006.
51. Simard J, Dumont M, Moisan A-M, Gaborieau V, Malouin H, et al. (2007) Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. Journal of Medical Genetics 44: 107-121 doi:10.1136/jmg.2006.044388.
52. Borg A, Haile RW, Malone KE, Capanu M, Diep A, et al. (2010) Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 31: E1200-40 doi:10.1002/humu.21202.
53. Díez Gilbert O, Machuca Cordano I, Angel Navarro M, (1996) [Characterization of the BRCA1 gene and its significance in hereditary breast cancer]. Med Clin (Barc) 107: 623-627.